Compare Natera Inc. Common Stock (NTRA) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Growth Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vanguard Growth Index Fund ETF trades at $88.85 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 6.7× Natera Inc. Common Stock's market cap, and Vanguard Growth Index Fund ETF is more actively traded (4,518,036 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| NTRA | VUG | |
|---|---|---|
Market Cap | $57.03B | $384.60B |
Volume | 1,131,157 | 4,518,036 |
Sector | Health | Sector/Thematic |
52-Week High | $425.64 | $92.64 |
52-Week Low | $179.42 | $70.00 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VUG trades at $91.75, up 0.12% with a bullish technical outlook supported by moving averages. The ETF maintains strong historical performance with 12% average annual returns since 2004, concentrated in mega-cap technology stocks like Nvidia, Apple, and Microsoft. Recent dividend activity shows a $0.09 distribution scheduled for September 2026.
Long-term growth prospects remain favorable given VUG's track record and low expense ratio, though concentration risk in technology holdings and recent underperformance versus value funds present headwinds. The ETF suits investors with multi-decade horizons seeking large-cap growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
